Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision

Authors: R Singer, P Campbell, C Fernandes, P Statham, D Hochhauser, J Bridgewater

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Patients with upper gastrointestinal malignancy often require admission to hospital with dysphagia or jaundice requiring therapeutic endoscopy. Endoscopic intervention is often effective permitting rapid discharge. An efficient service would permit rapid discharge for patients who are often at the end of life. We noted that a majority of patients in hospital under the gastroenterological oncology were admitted with symptoms requiring therapeutic endoscopy.

Methods

We conducted an audit cycle of the inpatient days before and after pathway implementation.
A wait of 1 day was set as acceptable for patients with bleeding as defined by NICE guidance and we set an arbitrary standard of 2 days for patients without bleeding but requiring therapeutic endoscopy. Between the audit cycles, a pathway was built to accommodate these patients.

Results

Inpatient waits improved from a median of 3 days to 1 day. There was no difference in outcome between those presenting with bleeding and other symptoms or any difference in patients requiring different procedures.

Conclusions

Waiting times for endoscopy can be improved with the introduction of a targeted pathway of cancer patients. Further issues including cost, quality of life and nutrition require further intervention.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Emanuel EJ, Emanuel LL. The economics of dying -- the illusion of cost Savings at the end of life. N Engl J Med. 1994;330:540–4.CrossRefPubMed Emanuel EJ, Emanuel LL. The economics of dying -- the illusion of cost Savings at the end of life. N Engl J Med. 1994;330:540–4.CrossRefPubMed
4.
go back to reference Raftery J, Addington-Hall J, MacDonald L, et al. A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med. 1996;10:151–61.CrossRefPubMed Raftery J, Addington-Hall J, MacDonald L, et al. A randomized controlled trial of the cost-effectiveness of a district co-ordinating service for terminally ill cancer patients. Palliat Med. 1996;10:151–61.CrossRefPubMed
5.
go back to reference Campbell HE, Stokes EA, Bargo D, et al: Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open. 2015;5. doi:10.1136/bmjopen-2014-007230. Campbell HE, Stokes EA, Bargo D, et al: Costs and quality of life associated with acute upper gastrointestinal bleeding in the UK: cohort analysis of patients in a cluster randomised trial. BMJ Open. 2015;5. doi:10.​1136/​bmjopen-2014-007230.
6.
go back to reference Benjamin A: Audit: how to do it in practice, 2008. Benjamin A: Audit: how to do it in practice, 2008.
Metadata
Title
Time to endoscopic intervention in patients with upper gastrointestinal patients can be improved with pathway provision
Authors
R Singer
P Campbell
C Fernandes
P Statham
D Hochhauser
J Bridgewater
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3335-0

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine